Media Release: Sydney, Australia. Wednesday 17 October 2012.

TGA APPROVAL OF PHEBRA NAPROXEN ORAL SUSPENSION

The Australian pharmaceutical company Phebra, announced today that the Therapeutic Goods Administration (TGA) has granted Phebra marketing approval for Naproxen oral suspension, an alternative to the previously available Naprosyn® oral suspension.

Phebra's Chief Executive Officer, Dr Mal Eutick, said: "Our Naproxen oral suspension formulation is, in all essential characteristics, closely identical to the previous product and is a crucial pain relief and anti-inflammatory medication especially in children.

"We at Phebra have always tried to assist with the supply of medication for children. We understand the importance of this suspension for younger patients to help with their pain management.

"That's why Phebra is pleased to have undertaken the development work required to manufacture and supply this very important formulation to the Australian market."

Naproxen oral suspension will be available in a 500mL bottle. It relieves pain and reduces inflammation occurring in various applications such as arthritis, including rheumatoid arthritis and osteoarthritis.

Dr Eutick said Phebra is working with the Pharmaceutical Benefits Scheme (PBS) to have the medicine re-listed on the PBS schedule.

ABOUT PHEBRA

Phebra is an Australian specialty pharmaceutical company which develops manufactures and markets critical medicines in Australia, New Zealand, Asia, Canada and parts of Europe.

The company's critical medicines cover a range of pharmaceuticals in important therapeutic areas such as cystic fibrosis, antidotes, diagnostics, oncology and pain.

At Phebra, we create critical medicines that save and improve lives.

Media contact: Richard Lenarduzzi at The Premier Communications Group on +61 2 9247 3337

Phebra Pty Ltd
332 Burns Bay Road, Lane Cove NSW 2066 Australia
Locked Bag 3003, Hunters Hill NSW 2110 Australia
T +61 (0)2 9420 9199 F +61 (0)2 9420 9177 W www.phebra.com
ABN 77 695 661 635